ARR-217
Gastrointestinal (GI) Tumors
PreclinicalLicensed from Lepu Biopharma
Key Facts
Indication
Gastrointestinal (GI) Tumors
Phase
Preclinical
Status
Licensed from Lepu Biopharma
Company
About ArriVent Biopharma
Founded in 2021, ArriVent Biopharma identifies and in-licenses promising drug candidates from global innovation hubs, particularly China, to develop them for worldwide markets. The company's mission is to ensure differentiated medicines for difficult-to-treat cancers reach global patient populations. Led by a team with a proven track record in drug development and approvals, ArriVent's strategy leverages deep oncology expertise and regulatory experience to maximize the potential of its pipeline.
View full company profile